Competing Cholesterol-Lowering Drugs Ready for AdCom Review
There is no shortage of companies targeting the cholesterol-lowering universe with drug candidates and several novel approaches are being tested in the clinic designed to lower the levels of LDL cholesterol in patients. In less than a month the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) will meet over the course of two days to render an opinion on two of these drugs. Both target the same indication – homozygous familial hypercholesterolemia (HoFH), a rare and generally fatal disease, but each has a different mechanism of action.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter